In a cohort study of 488 Danish patients, molecular reassessment showed efficacy of the treatment confined to patients with tumors harboring EGFR mutations,20 supporting international data.21 Erlotinib was established as SoC in Denmark in 2007 for patients with EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.